Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Seasonal vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Seasonal vaccine | ACTIVE_COMPARATOR | Seasonal influenza vaccination |
| Pandemic vaccine | EXPERIMENTAL | MF59-adjuvanted H5N1 monovalent vaccine |
| Name | Type | Description |
|---|---|---|
| Seasonal vaccine | BIOLOGICAL | Non-adjuvanted seasonal influenza vaccine (total dose 45ug) |
| H5 vaccine | BIOLOGICAL | MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose |
Inclusion Criteria: 1. Subjects aged over 18 years of age, mentally competent, who have signed an informed consent form after having received a detailed explanation of the study protocol; 2. Subjects willing to be enrolled in the vaccine study if appropriate from prescreening blood test results 3. ...
Seasonal vaccine is an investigational monoclonal antibody being developed for Influenza, an infectious disease. It is currently in Phase 1 clinical development. The vaccine is designed to address seasonal influenza, though specific efficacy data has not been disclosed.
Seasonal vaccine is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the vaccine's safety and immunogenicity in healthy volunteers.
Seasonal vaccine is currently in Phase 1 clinical development. It is an investigational product and has not been approved by regulatory authorities. The Phase 1 trial has been completed, with results not yet publicly reported.
Seasonal vaccine has one completed clinical trial, identified as NCT00798343, titled 'Heterosubtypic Immune Responses to Influenza in Older People.' This Phase 1 study enrolled 292 participants in the United Kingdom, including healthy volunteers aged 18 years and older.
Seasonal vaccine is not a traditional flu shot. It is a monoclonal antibody, a laboratory-made protein that mimics the immune system's ability to fight off pathogens. It is being investigated for its potential to provide immunity against influenza, but it is not a conventional vaccine.